PDCD1 and non-small cell lung carcinoma: The first data of such studies demonstrate that blockade of the PD-1/PD-L1 immune checkpoint improves progression-free survival in a fraction of NSCLC patients with an acceptable safety profile when given after radiotherapy or platinum-based radiochemotherapy [32,33].